Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Dummer, Reinhard; Hoeller, Christoph; Gruter, Isabella Pezzani; Michielin, Olivier (2017). Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunology, Immunotherapy, 66(6):683-695.

Deken, Marcel A; Gadiot, Jules; Jordanova, Ekaterina S; Lacroix, Ruben; van Gool, Melissa; Kroon, Paula; Pineda, Cristina; Geukes Foppen, Marnix H; Scolyer, Richard; Song, Ji-Ying; Verbrugge, Inge; Hoeller, Christoph; Dummer, Reinhard; Haanen, John B A G; Long, Georgina V; Blank, Christian U (2016). Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology, 5(12):e1238557.

Mangana, Joanna; Cheng, Phil F; Schindler, Katja; Weide, Benjamin; Held, Ulrike; Frauchiger, Anna L; Romano, Emanuella; Kähler, Katharina C; Rozati, Sima; Rechsteiner, Markus; Moch, Holger; Michielin, Olivier; Garbe, Claus; Hauschild, Axel; Hoeller, Christoph; Dummer, Reinhard; Goldinger, Simone M (2015). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: association with overall survival? PLoS ONE, 10(10):e0139438.

Goldinger, Simone M; Zimmer, Lisa; Schulz, Carsten; Ugurel, Selma; Hoeller, Christoph; Kaehler, Katharina C; Schadendorf, Dirk; Hassel, Jessica C; Becker, Juergen; Hauschild, Axel; Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50(2):406-410.

This list was generated on Tue Nov 21 21:31:17 2017 CET.